Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
0.900
-0.006 (-0.66%)
Mar 9, 2026, 3:11 PM EDT - Market open
Biodexa Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
754.91K USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 381.00K | -318.00K | -45.49% |
| Dec 31, 2022 | 699.00K | 121.00K | 20.93% |
| Dec 31, 2021 | 578.00K | 235.00K | 68.51% |
| Dec 31, 2020 | 343.00K | -331.00K | -49.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 4.49M |
| Onconetix | 1.22M |
| Lyra Therapeutics | 600.00K |
| PMGC Holdings | 285.95K |
| Aditxt | 5.95K |
| Virax Biolabs Group | 2.99K |
BDRX News
- 7 hours ago - Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients - GlobeNewsWire
- 18 days ago - Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer - Accesswire
- 4 weeks ago - Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST - GlobeNewsWire
- 2 months ago - Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary - GlobeNewsWire
- 2 months ago - Biodexa Announces Pricing of $10 Million Public Offering - GlobeNewsWire
- 3 months ago - Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP - GlobeNewsWire
- 3 months ago - Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP - GlobeNewsWire
- 4 months ago - Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion - GlobeNewsWire